Subject: Selective Internal Radiation Therapy (SIRT)*

Effective Date: April 28, 2009

Department(s): Utilization Management

Policy: Selective Internal Radiation Therapy (SIRT) with $^{90}$yttrium-containing resin spheres is reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to delineate circumstances under which a specific therapeutic intervention is to be authorized.

Procedure:

A. Diagnoses for which SIRT is reimbursable are:
   1. Primary hepatocellular carcinoma (ICD-9 155.0, ICD-10 C22.0)
   2. Metastatic hepatic lesions arising from colorectal cancer (ICD-9 197.7, ICD-10-C78.7)
   3. Metastatic hepatic lesions arising from neuroendocrine tumors(carcinoid, islet cell, pancreatic endocrine -ICD-9 197.7, ICD-10 C78.7)
   4. Unresectable intrahepatic cholangiocarcinoma (ICD 9-155.1, ICD-10 C22.1)

B. SIRT is not reimbursable for any other indication

C. CPT codes applicable to SIRT are:
   1. C2616 (for the $^{90}$yttrium-containing resin spheres)
   2. S2095 (for the deployment of the spheres)
References


Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2006;66(2Suppl):S62-S73 (Jan)

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.*